TBIO insider filings
Telesis Bio Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-07-26. Screen TBIO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TBIO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Telesis Bio Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-07-26 | 4 | Krueger Todd — Director | Grant/award (A): 8,390 @ $0 · Grant/award (A): 5,268 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Hodges Michael R. — Director | Grant/award (A): 8,390 @ $0 · Grant/award (A): 5,268 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Weissman James B — Director | Grant/award (A): 8,390 @ $0 · Grant/award (A): 5,268 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Hlavinka Sarah E. — Director | Grant/award (A): 8,390 @ $0 · Grant/award (A): 5,268 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Golub Steven J — Director | Grant/award (A): 8,390 @ $0 · Grant/award (A): 5,268 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | TUMOLO ANNETTE — Director | Grant/award (A): 46,752 @ $0 · Grant/award (A): 36,406 @ $0 · Grant/award (A): 70,129 (derivative) @ $0 · Grant/award (A): 30,362 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Witney Frank — Director | Grant/award (A): 46,752 @ $0 · Grant/award (A): 48,354 @ $0 · Grant/award (A): 70,129 (derivative) @ $0 · Grant/award (A): 30,362 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Herrema Gregory J. — Director | Grant/award (A): 31,486 @ $0 · Grant/award (A): 30,362 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | TSINGOS CHRISTINE A — Director | Grant/award (A): 46,752 @ $0 · Grant/award (A): 37,109 @ $0 · Grant/award (A): 70,129 (derivative) @ $0 · Grant/award (A): 30,362 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | NACHTSHEIM JAMI K — Director | Grant/award (A): 46,752 @ $0 · Grant/award (A): 34,297 @ $0 · Grant/award (A): 70,129 (derivative) @ $0 · Grant/award (A): 30,362 (derivative) @ $0 | EDGAR |
| 2024-04-19 | 4 | Esser Eric Eugene — President & CEO, Director | Grant/award (A): 100,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Nelson Todd Robert — Chief Executive Officer, Director, 10% owner | Grant/award (A): 47,700 @ $0 · Tax withholding (F): 4,756 @ $0.53 · Grant/award (A): 385,500 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Esser Eric Eugene — President & COO | Grant/award (A): 32,600 @ $0 · Tax withholding (F): 3,340 @ $0.53 · Grant/award (A): 263,600 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Gibson Daniel Glenn — Chief Technology Officer | Grant/award (A): 6,400 @ $0 · Tax withholding (F): 656 @ $0.53 · Grant/award (A): 51,500 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Cutler Rob — Chief Legal Officer | Grant/award (A): 13,800 @ $0 · Tax withholding (F): 1,376 @ $0.53 · Grant/award (A): 111,800 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | Nelson Todd Robert — President & CEO, Director, 10% owner | Tax withholding (F): 4,776 @ $0.53 | EDGAR |
| 2024-02-29 | 4 | Gibson Daniel Glenn — Chief Technology Officer | Tax withholding (F): 2,265 @ $0.53 | EDGAR |
| 2024-02-29 | 4 | Cutler Rob — Chief Legal Officer | Tax withholding (F): 2,174 @ $0.53 | EDGAR |
| 2023-12-05 | 4 | KULLBACK WILLIAM J — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-10-25 | 4 | Herrema Gregory J. — Director | Grant/award (A): 153,191 @ $0 · Grant/award (A): 229,787 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | MEISTER PAUL M — Director, 10% owner | Grant/award (A): 108,270 @ $0 · Grant/award (A): 162,406 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | Nelson Todd Robert — President & CEO, Director, 10% owner | Grant/award (A): 25,000 (derivative) · Grant/award (A): 528,922 (derivative) · Grant/award (A): 1,057,843 (derivative) | EDGAR |
| 2023-06-07 | 4 | Northpond Ventures GP, LLC — Director, 10% owner Northpond Ventures, LP — Director, 10% owner Rubin Michael P. — Director, 10% owner | Grant/award (A): 80,000 (derivative) @ $100 · Grant/award (A): 3,385,097 (derivative) @ $0 · Grant/award (A): 1,692,549 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | BroadOak Fund IV, LLC — 10% owner | Grant/award (A): 20,000 (derivative) · Grant/award (A): 423,137 (derivative) · Grant/award (A): 846,274 (derivative) | EDGAR |
| 2023-06-07 | 4 | Snider William — Director, 10% owner | Grant/award (A): 20,000 (derivative) · Grant/award (A): 423,137 (derivative) · Grant/award (A): 846,274 (derivative) | EDGAR |
| 2023-05-08 | 4 | Nelson Todd Robert — President & CEO, Director, 10% owner | Sale (S): 2,575 @ $2.83 | EDGAR |
| 2023-05-08 | 4 | Gibson Daniel Glenn — Chief Technology Officer | Sale (S): 1,190 @ $2.83 | EDGAR |
| 2023-05-08 | 4 | Cutler Rob — Chief Legal Officer | Sale (S): 1,174 @ $2.83 | EDGAR |
| 2021-09-16 | 4/A | BAUPOST GROUP LLC/MA — 10% owner Baupost Group GP, L.L.C. — 10% owner KLARMAN SETH A — 10% owner | Other (J): 18,044,239 @ $38 | EDGAR |
| 2021-09-14 | 4 | Sutherland Everett Rand — President | Sale (S): 300,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Smith Brendan — Chief Financial Officer | Sale (S): 201,800 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Burgess Paul D. — Chief Operating Officer, CLO | Sale (S): 71,833 @ $38 · Sale (S): 219,652 (derivative) @ $0 · Sale (S): 69,953 (derivative) @ $0 · Sale (S): 150,000 (derivative) @ $0 · Sale (S): 150,000 (derivative) @ $0 · Sale (S): 90,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Plenge Robert M — Director | Sale (S): 37,800 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Meyer Robert J. — Director | Sale (S): 18,900 (derivative) @ $0 · Sale (S): 37,800 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Demetri George — Director | Sale (S): 37,800 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Demetri George — Director | Sale (S): 37,800 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Hughes Owen — Director | Sale (S): 29,860 @ $38 · Sale (S): 38,135 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Beckman Daniella — Director | Sale (S): 67,995 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Renaud Ronald C JR — Chief Executive Officer, Director | Sale (S): 503,231 @ $38 · Sale (S): 409,913 @ $38 · Sale (S): 40,909 @ $38 · Sale (S): 500,000 (derivative) @ $0 · Sale (S): 525,000 (derivative) @ $0 · Sale (S): 325,000 (derivative) @ $0 · +2 more | EDGAR |
| 2021-09-14 | 4/A | Renaud Ronald C JR — Chief Executive Officer, Director | Option exercise (M): 9,026 @ $7.39 · Option exercise (M): 9,026 (derivative) @ $0 | EDGAR |
| 2021-09-14 | 4 | Sanofi — 10% owner | Purchase (P): 51,467,612 @ $38 · Purchase (P): 20,515,985 @ $38 | EDGAR |
| 2021-09-14 | 4 | FORMELA JEAN FRANCOIS — Director | Sale (S): 2,055,063 @ $38 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 18,900 (derivative) @ $0 · Sale (S): 20,000 (derivative) @ $0 · Sale (S): 37,800 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | FORMELA JEAN FRANCOIS — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Plenge Robert M — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Meyer Robert J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Demetri George — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Hughes Owen — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | Beckman Daniella — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-04-20 | 4 | Smith Brendan — Chief Financial Officer | Grant/award (A): 201,800 (derivative) @ $0 | EDGAR |
| 2021-04-09 | 4 | Renaud Ronald C JR — Chief Executive Officer, Director | Option exercise (M): 9,026 @ $7.39 · Option exercise (M): 9,026 (derivative) @ $0 | EDGAR |
Recent 8-K events — Telesis Bio Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-11-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2024-10-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-09-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-08-28 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2024-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-06-12 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TBIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs